Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i> -Rearranged/ <i>TP53</i> -Mutant NSCLC via Noxa Expression

Abstract

These clinical and preclinical results indicate concomitant <i>TP53</i> mutations reduce the efficacy of alectinib for <i>ALK</i>-rearranged NSCLC and the combined use of a proteasome inhibitor with alectinib is a promising therapy for <i>ALK</i>-rearranged/<i>TP53</i>-mutated NSCLC.